The EPHX1 antibody targets the enzyme epoxide hydrolase 1 (EPHX1), also known as microsomal epoxide hydrolase, which plays a critical role in metabolizing endogenous and exogenous epoxide compounds. EPHX1 is a member of the α/β-hydrolase fold superfamily and is primarily expressed in the liver, though it is also found in other tissues. It catalyzes the hydrolysis of reactive epoxides into less reactive diols, influencing detoxification pathways, drug metabolism, and the processing of environmental toxins. Dysregulation of EPHX1 has been linked to various diseases, including cancer, neurodegenerative disorders, and pulmonary conditions.
EPHX1 antibodies are widely used in research to study the enzyme's expression, localization, and function in cellular and pathological contexts. These antibodies enable detection of EPHX1 protein levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They are essential for investigating how genetic polymorphisms (e.g., Tyr113His or His139Arg) affect enzymatic activity or disease susceptibility. Additionally, EPHX1 antibodies help explore the enzyme's role in metabolizing carcinogens, chemotherapeutic agents, or environmental pollutants, providing insights into personalized medicine and toxicology. Validated antibodies are typically raised in hosts like rabbits or mice, with specificity confirmed using knockout controls or recombinant proteins. Researchers rely on these tools to unravel EPHX1's complex interactions in health and disease.